A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

The commercial launch of Casgevy continues to gain momentum ... At the same time, RNA molecules made in a lab could guide Cas proteins to exactly where to cut the DNA. The technique works in ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

This study shows that RNA decay rather than the presence of premature termination codons triggers a TA-like response.

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Alternative splicing (AS) of pre-mRNA plays a crucial role in tissue-specific gene regulation, with disease implications due to splicing defects. Predicting and manipulating AS can therefore uncover ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems.